我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

单硝酸异山梨醇乙酰阿魏酰胺的设计合成及对大鼠缺血心脏保护作用的研究

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第6期
页码:
696-701
栏目:
基础研究
出版日期:
2012-12-25

文章信息/Info

Title:
Synthesis and protective effect of isosorbide mononitrate acetyl ferulate amide on ischemic myocardium in rats
作者:
冯 力1; 唐秀玲2; 王平安2; 王剑波1; 孙晓莉2
(第四军医大学药学院：1.天然药物学教研室，2.化学教研室，陕西 西安 710032)
Author(s):
FENG Li1;  TANG Xiu-ling2;  WANG Ping-an2;  WANG Jian-bo1;  SUN Xiao-li2
(1.Department of Natural Medicine, 2.Department of Chemistry, School of Pharmacy, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
单硝酸异山梨醇乙酰阿魏酰胺; 一氧化氮供体; 心肌保护作用
Keywords:
isosorbide mononitrate acetyl ferulate;  nitric oxide donors;  cardioprotective effect
分类号:
R542.2
DOI:
-
文献标识码:
A
摘要:
目的:研制单硝酸异山梨醇乙酰阿魏酰胺（AcFA-201），并与阿魏酸钠（SF）、单硝酸异山梨醇酯（ISMN）和单硝酸异山梨醇乙酰阿魏酸酯（AFI）比较其对心肌缺血/再灌注（MI/R）大鼠心肌的保护作用。同时比较AcFA-201与AFI在模拟胃液中的稳定性。方法： 先将ISMN的羟基转化为胺基，再与乙酰化阿魏酰氯反应，生成新化合物AcFA-201。常规建立大鼠MI/R（30 min/3 h）模型，随机给予SF、ISMN、AFI或AcFA-201药物治疗。观察各组大鼠灌注末心功能恢复的情况，同时测定血清肌酸激酶（CK）、乳酸脱氢酶（LDH）、超氧化物歧化酶活性（SOD）、过氧化氢（H2O2）与丙二醛（MDA）的水平及NO的含量。结果： 合成路线可行，化合物AcFA-201的化学产率为81.8%。模拟胃液中的稳定性研究结果表明，AFI在给药10 min后，原药剩余很少，30 min完全消失；而AcFA-201在180 min后，基本保持初始给药浓度。与SF、ISMN治疗组相比，AcFA-201治疗组左室发展压、左室等容收缩压/舒张期压力上升或下降最大速率（±dp/dtmax）显著提高(n=8，P<0.05)。血清CK、LDH的活性和H2O2、MDA的含量降低而NO含量显著升高(n=8，P<0.05或P<0.01)；与AFI组相比，AcFA-201组各项指标均无显著性差异。结论： AcFA-201对MI/R损伤大鼠的心肌具有保护作用，其作用比SF、ISMN强，与AFI没有显著性差异。AcFA-201在模拟胃液中的稳定性明显优于AFI，更适合口服药物的研发。
Abstract:
AIM:To design and synthesize isosorbide mononitrate acetyl ferulate amide (AcFA-201) and to study the protective effect of AcFA-201 on myocardial ischemia/reperfusion (MI/R) injury in rats. We compared its effect with that of sodium ferulate (SF), isosorbide mononitrate (ISMN) and isosorbide mononitrate acetyl ferulic acid ester (AFI) and compared the stability of AFI and AcFA-201 in simulated gastric fluid. METHODS: We first translated the hydroxyl of ISMN into amino, caused it to react with acetylated ferulic oxychloride and then obtained AcFA-201 with chemical yield of 81.8%. Male Sprague Dawley rats were subjected to 30 min of myocardial ischemia and 3 h of reperfusion and then randomly received one of the following treatments separately: SF, ISMN, AFI or AcFA-201. The recovery of cardiac function was recorded and serum creatine kinase (CK) activity, lactate dehydrogenase (LDH) activity, superoxide dismutase (SOD) activity, hydrogen peroxide (H2O2) level, malondialdehyde (MDA) and nitric oxide (NO) content were determined at the end of reperfusion. RESULTS: Synthetic route was feasible and the chemical yield of AcFA-201 was 81.8%. Studies of the stability in simulated gastric fluid showed that little AFI remained after 10 min and disappeared in 30 min. Meanwhile, AcFA-201 retained the initial drug concentration even 180 min after dosing. Compared with SF and ISMN treatment groups, AcFA-201 treatment group significantly improved cardiac functions as evidenced by increasing left ventricular development pressure (LVDP) and ±dp/dtmax (n=8, P<0.05), reducing serum CK and LDH activities as well as H2O2 and MDA levels and obviously increasing NO content. However, no significant differences were observed between AcFA-201 group and AFI group. CONCLUSION: AcFA-201 showed a stronger cardioprotective effect against MI/R injury than SF and ISMN and there was no significant difference between AcFA-201 and AFI. AcFA-201 is more stable than AFI in simulated gastric fluid and AcFA-201 is thus more suitable for the development of oral drugs.

参考文献/References

[1]Gija L,Sujin C,Seung KK,et al.Real time dynamics of nitric oxide during cardiac ischemia-reperfusion of the rat[J].Sensors and Actuators B:Chemical,2012,3(1):480-485.
[2]Tamargo J,Caballero R,Gómez R,et al.Cardiac electrophysiological effects of nitric oxide[J].Cardiovasc Res, 2010,87(4):593-600.
[3]Ma H,Zhang HF,Gao F,et al.Vasculoprotective effect of insulin in the ischemic/reperfused canine heart:role of Akt-stimulated NO production[J].Cardiovasc Res,2006, 69(1):57-65.
[4]Yu QJ,Si R,Gao F,et al.Insulin inhibits beta-adrenergic action in ischemic/reperfused heart: a novel mechanism of insulin in cardioprotection[J].Apoptosis,2008, 13(2):305-317.
[5]陈汉辉.单硝酸异山梨酯联合复方丹参滴丸治疗不稳定型心绞痛的疗效观察[J].中外健康文摘,2009,6(2):185-186.
[6]Gao F,Yao CL,Ma XL,et al.Enhancement of glutathione cardioprotection by ascorbic acid in myocardial reperfusion injury[J].Pharmacol Exp Ther,2002,301(2):543-550.
[7]范谦,王文勇,高峰,等.大剂量硝酸甘油加重大鼠离体心脏缺血/再灌注损伤[J].心脏杂志,2005,17(3):204-206.
[8]刘文冲,孙晓莉,季乐乐,等.一种抗心肌缺血/再灌注损伤的新化合物的合成及心肌保护作用研究[J].药学学报,2009,44(3):321-326.
[9]向卓,孙晓莉,王平安,等. 乙酰丹参素单硝酸异山梨醇酯的合成及对心肌缺血/再灌注大鼠心脏的保护作用[J].第四军医大学学报,2009, 30(14):1257-1261.
[10]庄越,曹宝成,萧瑞祥,等.实用药物制剂技术[M].北京:人民卫生出版社,1999.
[11]叶盛英,王世岭,高申,等.重组人表皮生长因子在人工胃液和人工肠液中的稳定性[J].第二军医大学学报,2003,24(7):810-811.
[12]Gao F,Yue TL,Shi DW,et al.p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation[J].Cardiovasc Res,2002,53(2):414-422.

备注/Memo

备注/Memo:
收稿日期：2012-09-06.基金项目：国家科技重大新药专项基金资助(2009zx09301-009-PJ04)，“十二五”国家科技部科技支撑计划项目资助(2012BAK25B02) 通讯作者：孙晓莉，教授，主要从事心脑血管药物的研究 Email:xiaolis@fmmu.edu.cn 共同通讯作者：王剑波，教授，主要从事新药作用机制研究 Email:yyswjb@fmmu.edu.cn 作者简介：冯力，硕士生 Email:fengliaini@126.com
更新日期/Last Update: 2012-12-30